Using Isoflurane to treat severe epilepsy that doesn't respond to other treatments
Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus (I-Seizure)
This study is testing if Isoflurane can help adults with severe epilepsy that doesn't respond to other treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hopital of Melun Academic / other |
| Locations | 4 sites (Beuvry and 3 other locations) |
| Trial ID | NCT05830864 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of Isoflurane as a treatment for patients experiencing refractory status epilepticus. Data will be collected from four intensive care units (ICUs) on patients who were treated with Isoflurane between January 2016 and January 2023. The study will focus on patients over 18 years old who received Isoflurane as a third-line anticonvulsive therapy. By analyzing this data, researchers hope to determine the efficiency of Isoflurane in managing this severe condition.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been hospitalized in an ICU and treated with Isoflurane for refractory status epilepticus.
Not a fit: Patients with post-anoxic refractory status epilepticus following cardiac arrest or those who withdraw consent for data use may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a new therapeutic option for patients suffering from refractory status epilepticus.
How similar studies have performed: While the use of Isoflurane in this context is being assessed, similar studies have shown promise in using anesthetics for seizure control, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \> 18 years, hospitalized in ICU between 2016-01-01 and 2023-01-01, suffering refractory status epilepticus treated by inhaled Isoflurane as third anticonvulsive therapy Exclusion Criteria: * post-anoxic refractory status epilepticus after cardiac arrest, withdrawal of consent for medical data use
Where this trial is running
Beuvry and 3 other locations
- Ch Bethune Beuvry — Beuvry, France (Recruiting)
- CHU Brest — Brest, France (Recruiting)
- GH Sud Ile de France, Hôpital de Melun-Sénart — Melun, France (Recruiting)
- CH Toulon - Sainte Musse — Toulon, France (Recruiting)
Study contacts
- Study coordinator: Sebastien Jochmans, Md
- Email: sebastien.jochmans@ghsif.fr
- Phone: 0181742078
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.